Japan Approves Dupixent for Chronic Spontaneous Urticaria (CSU) Becoming First in the World to Do So
This makes CSU treatment the sixth approved use globally.
japanese flag © somartin - stock.adobe.com
The Ministry of Health, Labor and Welfare (MHLW) in Japan granted marketing and manufacturing authorization for Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU), according to today’s Regeneron and Sanofi press release.
CSU is characterized by recurrent and itchy hives often triggered by temperature or pressure on the skin. Both adults and children can be affected but it is twice as common in adult females. It is associated with immune disorders like food allergies and hypothyroidism.
About 110,000 people in Japan aged 12 years and older currently suffer from uncontrolled moderate to severe CSU. In the United States, 1% of the population is affected at any given time.
Dupixent is also used to treat atopic dermatitis and asthma with 800,000 being treated globally.
Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults
May 7th 2025A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.
Read More
Patients With Atopic Dermatitis Turn to Social Media but Trust Medical Advice Most
May 5th 2025A study found that while patients with atopic dermatitis often turn to social media for skincare advice, their decisions are most influenced by healthcare professionals, personal experience, and disease severity.
Read More
Most Patients With HS Aren’t Aware of Approved Treatments
May 1st 2025Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.
Read More
